Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600_W604delinsR |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600_W604delinsR | lung adenocarcinoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a partial response after 48 days, shrinkage of metastatic lesions, and decreased pleural effusion in a patient with advanced lung adenocarcinoma harboring BRAF V600_W604delinsR (PMID: 38766698). | 38766698 |
PubMed Id | Reference Title | Details |
---|---|---|
(38766698) | Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient. | Full reference... |